First Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL™ in Patients with Parkinson’s Disease Tungsten
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised its option to cancel
Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS)
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter
MIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth
Investigational Oral Candidate JOTROL™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc.
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE:MDMA, OTCQB:MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development, and manufacturing of novel MDXX-class
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE
